This website is no longer being updated. Please visit GBCHealth’s new website at: www.gbchealth.org.

MEMBER PROFILES

JN-International Medical Corp.

Company Overview

Since the founding of the company in 1997, JN has focused its energies and based its success on innovative vaccines and diagnostics, sound business strategy, and a passion for people around the world, who receive our products. By prioritizing the elements in the creation of the company and staying true to these priorities, we have become one of the world's leading biotechnology company practice of world class medicine with our groundbreaking scientific discoveries, bringing to market the rapid, conventional diagnostics first, proving the commercial viability of this new technology through recognition for our forward-thinking. They are the blueprint upon which we have built and continue to grow our company. They are at the core of who we are now based in the Midwestern region of the United States.

Our mission is to be the leading biotechnology company, using genetic engineering technology to discover, develop, and commercialize diagnostics and vaccines that address significant medical needs. We commit ourselves to high standards of integrity in contributing to the best interests of international communities, and to seeking significant returns, based on the continual pursuit of scientific and operational excellence.

HIV/AIDS Profile

HIV rapid test product details:
http://www.jn-vaccines.org/JN-hiv_3.pdf

HIV Vaccine Initiative
http://www.jn-vaccines.org/JNHIV-DNA-Vaccine.pdf

Tuberculosis Profile

The United States-based JN-International Medical Corporation opened its first overseas branch in 2005 in Abidjan, Côte d'Ivoire and later in 2006 in Ouagadougou, Burkina Faso. Operating in Africa enables the company to more efficiently store and distribute many of its products. By February 2007, the company plans to supply two million diagnostic tests for Malaria and TB to West Africa.

Tuberculosis:
The Tuberculosis epidemic is increasing the spread of multidrug-resistant strains of TB, which kills some 1,500 Africans every day. MDR-TB rates are rising in both Africa and parts of Eastern Europe. Africa is particularly hit because of co-infections with HIV and a lack of health infrastructure to monitor and treat the disease. Despite commendable efforts by countries and partners to control tuberculosis, their impact has not been significant and the epidemic has now reached unprecedented proportions.

TB Rapid Diagnostic:
In 2002 JN developed a rapid diagnostic test for the detection of Mycobacterium tuberculosis. Most standard tests for the detection of Tuberculosis, such as skin tests, X-rays, and DNA techniques, are expensive and time consuming. JN was able to design a test that was ideal for in-the-field diagnosis of Tuberculosis. It is an affordable, accurate, and easy to use immunochromatographic serological assay for the rapid detection of tuberculosis and multi drug-resistant tuberculosis. The TB test showed to be highly effective, with a sensitivity of 99.52% and a specificity of 99.42%. These results, published in Comparative Immunology, Microbiology & Infectious Diseases (2002), show that JN's TB rapid diagnostic tests are an important tool in the first-line testing of suspected TB cases in the field. These tests have been used throughout the world, in locales that include India, South America, and Africa.

TB Vaccine:
Tuberculosis is one of the leading causes of infectious disease-related mortality worldwide, and vaccines have been the primary preventive therapy for many decades. Currently, Mycobacterium bovis bacille Calmette-Guérin (BCG), an attenuated live bacteria, is the only approved tuberculosis vaccine available. BCG vaccination has variable success in preventing acute tuberculosis infection and after the emergence of Multi Drug Resistant TB strains ((MDR TB), prompting the search for new methods of vaccination. JN has also initiated research on developing an inexpensive DNA vaccine against Tuberculosis that can protect from M. tuberculosis (MDR TB) strains. Initial research on the vaccine done on animals indicates that this vaccine may not only prevent TB but also be effective against MDR TB. Much research remains to be done on this topic, but the scientists at JN remain dedicated to preventing infectious disease throughout the world.

More information about this vaccine and JN's other vaccines can be found at http://www.jn-vaccines.org/ and Diagnostics web site at http://www.jnii-usa-bharat.com/.

Malaria Profile

The United States-based JN-International Medical Corporation opened its first overseas branch in 2005 in Abidjan, Côte d'Ivoire and later in 2006 in Ouagadougou, Burkina Faso. Operating in Africa enables the company to more efficiently store and distribute many of its products. By February 2007, the company plans to supply two million diagnostic tests for Malaria and TB to West Africa.

JN markets the most acceptable malaria rapid diagnostic test kit in Africa, which detects the antigens of lactate dehydrogenase (pLDH) and can differentiate between malaria caused by P. falciparum and that caused by P. vivax, P. malariae, and P. ovale. This pLDH test has a sensitivity of 96% and a specificity of 98.5%, confirmed by Pasture Research Institutes in Ivory Coast and in Madagascar. The ability to accurately diagnose malaria is the first step in being able to help those infected.

JN-International Medical Corporation has a complete selection of rapid diagnostics available for export from the United States.